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Abstract 
BACKGROUND: Impairment in domain-specific cognitive function is associated with 
the increased risk of mortality. We prospectively evaluated the association of 
executive function and memory with the risk of long-term mortality in dementia-free 
older subjects. Moreover, we investigated the role of structural brain abnormalities in 
this association. 
METHODS: We included 547 dementia-free participants (mean age 78 years, 56.5% 
male) from the nested magnetic resonance imaging sub-study of the PROspective 
Study of Pravastatin in the Elderly at Risk (PROSPER). Cox proportional hazard 
models were used to model 10-year risk of all-cause, cardiovascular and non-
cardiovascular mortality in relation to performance in executive function and memory. 
Moreover, we evaluated the role of total brain parenchymal volume, cerebral blood 
flow, white matter hyperintensity and the presence of microbleeds and infarcts in the 
link between cognitive function and mortality. 
RESULTS: In the multivariable model, lower performance in executive function was 
associated with greater risk of all-cause (hazard ratio [HR] 1.49, 95% confidence 
interval [CI] 1.31-1.70), cardiovascular (HR 1.69, 95%CI 1.36-2.11) and non-
cardiovascular (HR 1.36, 95%CI 1.15-1.62) mortality. Similarly, poorer performance 
in memory tests associated with higher risk of all-cause (HR 1.47, 95%CI 1.29-1.68), 
cardiovascular (HR 1.45, 95%CI 1.15-1.83) and non-cardiovascular (HR 1.49, 
95%CI 1.27-1.76) mortality. The associations were similar in subjects with various 
levels of brain structural abnormalities and cerebral blood flow (all p for interaction 
>0.05). 
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CONCLUSIONS: Poorer performance in both executive function and memory tests 
associates with all-cause, cardiovascular and non-cardiovascular mortality in elderly 
individuals. This association is independent of cardiovascular risk factors and 
diseases, brain structural abnormalities and cerebral blood flow. 
 
KEYWORDS: Executive Function, Memory, Mortality, Structural Brain Abnormalities, 
Older Subjects 
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Background 
Patients with advanced dementia have a higher mortality rate and are at excess risk 
for cardiovascular events 1-3. Although the link between global cognitive impairment 
and mortality is well-established, only a few studies have investigated the relation of 
domain-specific cognitive function and mortality, with conflicting findings 4, 5. It has 
been suggested that different domains of cognitive function provide heterogeneous 
information in relation to health and survival. For instance, executive function, as 
compared to other cognitive domains, might better identify subjects at an increased 
risk for cardiovascular events 4-7. 
Neuroimaging studies have shown that older subjects with cognitive dysfunction 
have greater loads of subclinical structural brain abnormalities including white matter 
hyperintensity, atrophy, microbleeds and infarcts 8-13. Such brain structural 
abnormalities are also related to a shorter survival. Hence, it has been hypothesized 
that cognitive impairment might be an early manifestation of clinically unrecognized 
cerebral and systemic vascular pathologies which signals future risk of 
cardiovascular events and mortality 3, 6, 14. 
In this study we aimed, firstly, to evaluate the risk of all-cause, cardiovascular and 
non-cardiovascular mortality in relation to performance in cognitive domains of 
executive function and memory; and secondly, to determine this association is 
independent of structural brain abnormalities and cerebral blood flow. 
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Methods 
Study participants  
Data were extracted from the magnetic resonance imaging (MRI) sub-study of the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a prospective 
randomized controlled trial that of elderly men and women over 70 years old.  
At the initial visit, all participants gave their informed consent and a brief medical 
history was taken. The vital signs recorded, and appropriate health and dietary 
advice given. Subjects who satisfied the eligibility criteria were invited to attend the 
other screening visits at the beginning of the trail and also during the follow-up 
period. In the next steps, a more detailed medical history was taken, a fasting 
venous blood sample for biochemical and hematologic factors checks were 
collected. Moreover, the subject’s weight, height, and blood pressure were recorded 
and the mental and physical ability tests were controlled. Three national 
administrative centres, based in Scotland, Ireland and the Netherlands were 
responsible for recruiting participants, providing clinician support to the study nurses 
and investigators, managing the flow of trial medication and data, recording and 
reporting adverse events, and servicing the study committees. All data were 
preserved in the data centre, located at the university of Glasgow in the Robertson 
Centre for Biostatistics 15. 
The original aim of PROSPER was to evaluate the effect of pravastatin in older 
participants with pre-existing or at high risk of cardiovascular diseases. Exclusion 
criteria included congestive heart failure (New York Heart Association class III/IV), 
arrhythmia and impaired cognition (Mini-Mental State Examination score lower than 
24 points 16). Detailed inclusion and exclusion criteria and data collection have been 
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described extensively elsewhere 15, 17. In this sub-study of PROSPER, we included 
547 Dutch participants with MRI measurements at the end of the official PROSPER 
trial, with complete follow-up for mortality and with at least one completed cognitive 
function measurement taken at the time of MRI. All participants in this MRI sub-study 
underwent cognitive assessment and brain MRI in 2002 and followed for 10 years. 
Cognitive tests and settings  
A battery of cognitive tests were administered to evaluate the performance of 
domain-specific cognitive function at baseline, during follow-up and at the end of the 
PROSPER trial 18. The Stroop Colour-Word Test was used to test selective attention. 
Individuals were asked to read or name printed cards as quick as possible in three 
steps: (1) coloured names printed in black ink, (2) coloured patches, and (3) 
coloured names printed in incompatible coloured ink. The main outcome variable is 
the time needed to complete the third test. The Letter Digit Substitution Test is a 
paper-based task to test processing speed. Individuals are asked to fill in digits 
beside letters as quickly as possible, according to a key presented at the top of the 
test sheet. The main outcome variable is the number of correctly matched letter-
digits during a 60-second test procedure.  
The Picture Learning Test is used to test immediate and delayed memory 
performance. Fifteen pictures are presented sequentially, 2 seconds for each, after 
which subjects are asked to recall as many as picture as possible. To measure 
immediate memory, the same process is repeated 3 times. Delayed recall is tested 
after 20 minutes. The main outcome variable for both immediate and delayed 
memory is the average number of recalled pictures. For this study, tests were 
standardized and results were converted into Z-scores. By averaging the Z-scores of 
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the Stroop Colour-Word Test and the Letter Digit Substitution Test, a composite 
executive function was constructed and by averaging Z-scores of immediate and 
delayed memory, a composite memory score was created.   
MRI scanning 
MRI was performed at baseline and after three years of follow-up at 1.5 Tesla field 
strength on a clinical MR-system operating (Philips Medical Systems, Best, The 
Netherlands). Dual fast spin echo (repetition time=3,000 milliseconds; echo 
time=27/120 milliseconds; flip angle=90°; slice thickness=3 millimetres; 48 slices; no 
inter slice gap; field of=220×220 millimetres; matrix=256×204), fluid-attenuated 
inversion recovery (FLAIR) (repetition time=8,000 milliseconds; echo time=100 
milliseconds; flip angle= 90°; slice thickness=3 millimetres; 48 slices; no inter slice 
gap; field of view=220×176 millimetres; matrix=256×153), and T2* weighted images 
(multi slice gradient echo sequence; repetition time=2593 milliseconds; echo 
time=48 milliseconds; flip angle=60°; slice thickness=6 millimetres; 22 slices; inter 
slice gap=6 millimetres; whole-brain coverage; field of view=220×198 millimetres; 
matrix=256×176) were obtained. In addition, single slice phase contrast MR 
angiography (TR/TE=16/9 milliseconds; flip angle=7.5°; slice thickness=5millimetres; 
FOV=250; RFOV=75%; scan percentage=80%; matrix=256; 8 signal averages) with 
a velocity encoding of 100 centimetres per second was used for flow measurements 
19.  
MRI analyses 
The SIENAX (Structural Image Evaluation using Normalization of Atrophy) technique 
was used to obtain estimates of total parenchymal brain volume. By using Software 
for Neuro-Image Processing in Experiment Research (SNIPER), an in-house 
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developed program for image processing, quantification and presence of white 
matter hyperintensities, cerebral microbleeds and infarcts were automatically 
computed. Hyperintense lesions on T2*-weighted proton density images were 
defined as white matter hyperintensities. Focal areas of signal loss on T2*-weighted 
images that increased in size on the T2*-weighted gradients-echo planar images 
were defined as cerebral microbleeds. For cerebral blood flow assessment, images 
were analysed using the software package FLOW. The flow in vessels was summed 
giving the cerebral blood flow in millilitre per minute. Cerebral blood flow was also 
expressed in millilitre blood per 100 millilitres of brain parenchyma per minute 19-22.  
Outcomes 
Participants were followed-up for mortality for approximately 10 years after the 
official end of the PROSPER study. Dates of death were obtained from the Dutch 
municipal registry and specific causes of death were obtained from the Central 
Bureau of Statistics of The Netherlands. All endpoints were adjudicated by the 
independent local clinical events committee of PROSPER. The underlying cause of 
death from a death certificate was coded according to the International Classification 
of Diseases and Related Disorders, 10th revision, 1992. Death due to coronary heart 
diseases and cerebrovascular accidents were categorized as cardiovascular 
mortality and death from other complications including cancers, respiratory 
disorders, and neuropsychiatric diseases were categorized as non-cardiovascular 
mortality. All-cause mortality was defined as cumulative cardiovascular and non-
cardiovascular mortality. 
Covariates 
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Age, sex and educational attainment were recorded as socioeconomic 
characteristics of participants. Cardiovascular risk factors including history of 
smoking, systolic and diastolic blood pressures, body mass index, total cholesterol, 
creatinine, the presence of apolipoprotein 4, randomization to pravastatin treatment 
or placebo and antihypertensive treatment, history of diabetes and history of pre-
existing vascular diseases (coronary, cerebral, or peripheral) were recorded at 
baseline, during follow-up time and at the end of the trail. The last available values 
measured during the follow-up time or at the end of the original study was 
considered as characteristics of this sub-study of the PROSPER. Cognitive 
performance and brain MRI measurements were measured at the end of the of the 
official trial at the same time with last cognitive test measurements.  
Statistical analyses 
Characteristics of subjects were reported as mean with standard deviation (SD) or 
median with interquartile range (if the data were skewed) for continuous variables 
and frequency with the percentage for categorical variables in the total population. 
Entry time variable in this study was the time each participant underwent cognitive 
assessment. Participants were censored at the end of follow up time or if death 
occurred, whichever comes first. In this study, no participant lost to follow-up. 
Mortality data was available for all participants; hence, no right censoring was 
present in this study. 
Incident rates of mortality per 1000 person-years were calculated by dividing the 
number of deaths by person-years at risk. Cox proportional hazard models were 
used to model 10-year risk of all-cause, cardiovascular and non-cardiovascular 
mortality in relation to cognitive performance in composite executive function and 
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composite memory as well as each cognitive test independently. In addition, the 
relationships between cognitive function and all-cause, cardiovascular and non-
cardiovascular mortality were analysed in categories of brain abnormalities including 
the presence of microbleeds, infarcts and thirds of total brain volume, white matter 
hyperintensities and cerebral blood flow. In fully adjusted models, we tested the 
interactions between cognitive measures and categories of brain measures in 
relation to mortality outcomes. Time to death was used as the outcome variable, 
whereby performances in the various cognitive functioning tests were used as 
determinants. Associations between cognitive impairment and mortality were 
reported as hazard ratios (HR) with 95% confidence intervals (CI). Hazard ratios 
were calculated for each unit decrease in standardized domain-specific cognitive 
function. Analyses were performed in multiple phases: First, crude analyses were 
performed. In the next step, analyses were adjusted for socioeconomic 
characteristics including age, sex and education. In the third phase, analyses were 
further adjusted for cardiovascular factors including body mass index, history of 
smoking habit, systolic blood pressure, diastolic blood pressure, total cholesterol, 
creatinine, the presence of apolipoprotein 4, antihypertensive treatment, statin 
treatment, history of diabetes and history of pre-existing vascular diseases 
(coronary, cerebral, or peripheral). Moreover, analyses were further adjusted for total 
brain parenchymal volume, cerebral blood flow, white matter hyperintensity and the 
presence of microbleeds and infarcts. The proportional hazard assumption was 
tested using scaled Schoenfeld residuals and graphical methods by plotting log(-
log(S(t))) versus time and look for parallelism. In addition, we conducted stratified 
analyses to ensure that our findings were not different in various subgroups of 
participants. Kaplan-Meier curves were produced in order to compare risk of all-
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cause, cardiovascular and non-cardiovascular mortality according to thirds of 
executive function and memory.  
The association of cognitive performance and mortality was evaluated in interaction 
with total brain parenchymal volume, white matter hyperintensity load, cerebral blood 
flow, and the presence of microbleeds or infarcts. Interaction terms were produced 
by multiplying cognitive functioning test scores and brain MRI measurements.  
Moreover, all statistical analyses were performed using SPSS software (version 
23.0.0; SPSS Inc., Chicago, IL). Curves and plots were produced by GraphPad 
Prism 6 (GraphPad Software, Inc., La Jolla, CA).  
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Results 
Table 1 shows socioeconomic characteristics, cardiovascular factors, cognitive 
performance and brain MRI measurements of the participants. The mean age was 
78 (SD: 3.2) years and 56.5% were male. 
At the end of 10-year follow-up, 268 (49.0%) of participants had died. Among those, 
87 (15.9%) individuals deceased due to cardiovascular events and 179 (32.7%) 
subjects due to non-cardiovascular bases. Cause of mortality in two (0.4%) 
participants was unknown. 
The crude incidence rate of all-cause mortality was 62.7 (95%CI 55.7-70.3) deaths 
per 1,000 person-years. The incidence rates of cardiovascular and non-
cardiovascular mortality were 20.5 (95%CI 16.6-25.2) and 42.2 (95%CI 36.4-48.6) 
per 1,000 person-years respectively.  
Table 2 shows the risk of all-cause, cardiovascular and non-cardiovascular mortality 
dependent on the level of performance in executive function and memory. In the 
multivariable model, the risk of all-cause mortality was increased by 49 percent (HR 
1.49, 95%CI 1.31-1.70) per one standard deviation decline in executive function and 
47 percent (HR 1.47, 95%CI 1.29-1.68) per one SD decrease in memory domain. 
Cardiovascular mortality was increased by 69 percent (HR 1.69, 95%CI 1.36-2.11) in 
relation to executive function and 45 percent (HR 1.45, 95%CI 1.15-1.83) in relation 
to memory per one SD decline in performance of each domain-specific cognitive 
function. Similarly, non-cardiovascular mortality was elevated by 36 percent (HR 
1.36, 95%CI 1.15-1.62) and 49 percent (HR 1.49, 95%CI 1.27-1.76) per one SD 
decline in performance of the executive function and memory respectively.  
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In order to minimize the heterogeneity of the participants and to remove potential 
confounders for accusation between cognitive performance and risk of mortality, we 
adjusted all analyses for structural brain abnormalities (supplementary data table S-
1). Additionally, the risk of 10-year mortality in relation to performance in each 
standardized cognitive test was presented in the supplementary data table S-2. 
Figure 1 presents the cumulative risk of all-cause, cardiovascular and non-
cardiovascular mortality in thirds of composite executive function score and 
composite memory score. Compared to subjects with higher performance in domain-
specific cognitive functions, subjects with worse performance were at greater risk of 
all-cause, cardiovascular and non-cardiovascular mortality.  
Figure 2 shows the risk of 10-year all-cause mortality in thirds of total brain volume, 
white matter hyperintensities and cerebral blood flow in relation to performance in 
executive function and memory, adjusted for socioeconomic and cardiovascular risk 
factors. There was no statistically significant difference between thirds of total brain 
volume and white matter hyperintensities in the performance of both domains (all p 
for interactions >0.05) (Figure 2-A and 2-B). The risk of 10-year all-cause mortality in 
relation to the performance of memory was different in subjects at thirds of cerebral 
blood flow (p=0.033). Individuals at the highest third of cerebral blood flow were at 
lower risk of all-cause mortality compared to subjects at the lowest third. However, 
when the cause of death came into consideration, even in some points the 
association or the same trend were seen, but the difference between groups was not 
statistically significant (Figure 2-C).  
Figure 3 presents the risk of 10-year mortality in the presence or absence of 
microbleeds and infarcts. All results were adjusted for socioeconomic and 
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cardiovascular risk factors. Similarly, the risk of 10-year mortality was not statistically 
different between groups. The risk of 10-year all-cause (table S-3 and S-4), 
cardiovascular (table S-5 and S-6) and non-cardiovascular (table S-7 and S-8) 
mortality in relation to structural brain abnormalities with the performance in each 
standardized cognitive test, adjusted for socioeconomic and cardiovascular risk 
factors, are presented as supplementary data.  
Figure 4 shows the association of executive function and memory with the risk of 
mortality remained unchanged in various subgroups of participants with and without 
comorbidities.  
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Discussion 
In this long-term prospective study of older individuals, we showed that poorer 
performance in various cognitive domains, independent of socioeconomic and 
conventional cardiovascular risk factors, was associated with greater risk of 10-year 
all-cause, cardiovascular and non-cardiovascular mortality. Moreover, we were not 
able to show that these associations could be explained by brain structural 
abnormalities or cerebral blood flow. 
Our finding of the association between cognitive impairment and shorter survival is in 
line with previous reports 3, 23, 24. Different explanations have been proposed for this 
association. Firstly, it was suggested that lower performance in cognitive function 
was associated with lower socioeconomic status and the higher burden of chronic 
medical conditions leading to an increased mortality 23. In addition, individuals with 
cognitive deficits are at a higher risk for poorer self-care, such as medications 
adherence, health literacy and healthy lifestyle which might predispose them to 
cardiovascular and non-cardiovascular events 25-27. Secondly, it was proposed that 
lower cognitive function, may be attributed to the effects of decreased biological 
vitality leading to lower survivals among elderly subjects 24. Another explanation can 
be that cognitive performance in old age might be a reflection of vascular health. 
Cognitively impaired subjects are more likely to be exposed to life-long vascular risk 
factors 28, 29 and therefore, have greater vascular pathologies 30, 31, which increase 
the risk of mortality. The fourth possible explanation is related to the necessity of 
neural plasticity and integrity of the brain for the optimal brain and body functioning 
32. 
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It has been demonstrated that existing structural brain abnormalities including white 
matter hyperintensities, infarcts, microbleeds and decreased cerebral blood flow are 
strongly related to worse cognitive performance 33-35. On the other hand, we and 
others have shown that impaired brain structural integrity and lower cerebral blood 
flow are associated with higher risk of mortality in older adults 8, 36. Hence, brain 
lesions and impaired cerebrovascular hemodynamics have been proposed as major 
mechanisms behind the link between cognitive impairment and mortality. However, 
in this study, we observed that the relationships between cognitive function and 
mortality outcomes were independent of a variety of brain structural abnormalities 
and cerebral blood flow. A possible explanation is that both cognitive dysfunction and 
structural brain abnormalities reflect the lack of brain structural and functional 
integrity which make subjects more vulnerable for morbidities and put individuals at 
an increased risk of mortality 37. In addition, cognitive dysfunction and brain structural 
abnormalities have shared socioeconomic and cardiovascular risk factors and can 
be epiphenomenon which might explain that the link between impaired cognitive 
function and survival is not secondary to the established brain structural lesions or 
blood abnormalities. Hence, other mechanisms might play roles in this association 
which warrants further investigations 38-40. This may call for earlier intervention in 
midlife and young adulthood to preserve brain health and integrity.  
Several strengths and limitations of this study need to be acknowledged. As a 
strength, this study includes long follow-up time and availability of data for 
socioeconomic status, a wide range of cardiovascular factors, comorbidities and 
different cognitive domains. As a limitation, all participants in this study had relatively 
preserved cognitive function, which limits the generalizability of our findings to older 
adults with dementia. Furthermore, we included subjects with the history of 
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cardiovascular risk factors and pre-existing vascular diseases, which might also limit 
the generalizability of our findings, although a great number of older community-
dwelling participants carry a high load of cardiovascular diseases. However, 
adjustment for cardiovascular factors did not alter the associations between 
cognition and mortality. In addition, by conducting sensitivity analyses, we showed 
that our findings were not dependent upon particular vascular risk factors and 
diseases. Patients with mild cognitive impairment (MCI) can be considered as a 
high-risk group which might benefit from early interventions to improve their survival 
and well-being in long-term. Future studies can address the links between various 
subtypes of MCI and cause-specific mortality. 
 
 
 
 
 
 
 
 
 
 
  
18 
 
Conclusions 
Our results suggest that lower performance in domains of executive function and 
memory associates with all-cause, cardiovascular and non-cardiovascular mortality 
in elderly individuals. Hence, the cognitive assessment could be considered as a 
potential strategy, along with the other clinical tools, to identify elderly subjects at 
greater risk of mortality. Moreover, our data suggest that structural brain 
abnormalities per se do not play a key role in cognitive function-mortality link in 
dementia-free older subjects.  
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Table 1: Characteristics of study participants (n=547) 
 
 
All last available data measured at the end of the original PROSPER were considered as the 
characteristics of this study. 
 
Abbreviations: n: number, SD: standard deviation, kg/m2: kilogram per meter squared, 
mmHg: millimetres of mercury, mmol/L: millimoles per litre, cc: cubic centimetre; ml: 
millilitres; min: minute: IQR: interquartile range. 
 
 
 
 
Characteristics 
 
Values 
 
 
Socioeconomics Characteristics 
 
Male, n (%) 309 (56.5) 
Age, mean (SD) 78.3 (3.2) 
Age left school, mean (SD) 15.5 (2.9) 
Cardiovascular Factors  
History of smoking, n (%)   378 (69.1) 
Body mass index, kg/m2, mean (SD) 26.6 (3.7) 
Systolic blood pressure, mmHg, mean (SD) 155.8 (20.6) 
Diastolic blood pressure, mmHg, mean (SD) 83.9 (9.8) 
Total cholesterol, mmol/L, mean (SD) 4.9 (1.0) 
Creatinine 95.4 (17.7) 
Presence of apolipoprotein 4 150 (27.4) 
History of vascular disease, n (%) 262 (47.9) 
History of diabetes, n (%) 122 (22.3) 
History of pravastatin treatment, n (%) 273 (49.9) 
History of antihypertensive treatment, n (%) 346 (63.3) 
Cognitive Performance    
Mini-mental state examination, points, median (IQR) 29 (28-30) 
Stroop Colour-Word test, seconds, median (IQR) 50.6 (42.1-64.5) 
Letter-Digit Substitution test, digits per minute, mean (SD) 26.3 (7.4) 
Immediate Picture Learning test, words, mean (SD) 10.1 (2.2) 
Delayed Picture Learning test, words, mean (SD) 11.1 (3.1) 
Brain MRI Measurements   
Total brain volume, ml, mean (SD) 1359.2 (65.9) 
Cerebral blood flow, ml/100ml/min mean (SD) 47.6 (8.9) 
White matter hyperintensities, total volume, ml, median (IQR) 2.8 (0.8-9.2) 
Infarcts, n (%) 180 (32.9) 
Microbleeds, n (%) 104 (19.0) 
3 
 
Table 2. Domain-specific cognitive function and risk of 10-years mortality (n=547) 
 
Abbreviations: CV: Cardiovascular; HR: Hazard Ratio; CI: Confidence Interval. 
Model 1: Adjusted for age, sex and education. Model 2: Model 1 adjusted further for body mass index, history of smoking 
habit, systolic blood pressure, diastolic blood pressure, total cholesterol, creatinine, presence of apolipoprotein 4, 
antihypertensive treatment, statin treatment, history of diabetes and history of vascular diseases.  
 
  
All-cause Mortality 
 
 
CV Mortality 
 
Non-CV Mortality 
 
Cognitive Domain 
 
 
HR (95%CI) 
 
p-value 
 
HR (95%CI) 
 
 
p-value 
 
HR (95%CI) 
 
p-value 
 
Executive Function  
 
      
Crude, HR (95%CI) 
 
1.54 (1.37-1.72) <0.001 1.82 (1.52-2.17) <0.001 1.39 (1.19-1.61) <0.001 
Adjusted model 1, HR (95%CI) 
 
1.47 (1.30-1.67) <0.001 1.75 (1.43-2.13) <0.001 1.33 (1.14-1.56) <0.001 
Adjusted model 2, HR (95%CI) 
 
1.49 (1.31-1.70) <0.001 1.69 (1.36-2.11) <0.001 1.36 (1.15-1.62) <0.001 
 
Memory  
 
      
Crude, HR (95%CI) 
 
1.54 (1.37-1.72) <0.001 1.56 (1.28-1.92) <0.001 1.54 (1.32-1.79) <0.001 
Adjusted model 1, HR (95%CI) 
 
1.45 (1.28-1.64) <0.001 1.45 (1.18-1.82) 0.001 1.47 (1.25-1.69) <0.001 
Adjusted model 2, HR (95%CI) 
 
1.47 (1.29-1.68) <0.001 1.45 (1.15-1.83) 0.002 1.49 (1.27-1.76) <0.001 
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Figure 1. Risk of mortality in association with cognitive assessments 
 
 
Abbreviation: CV: cardiovascular.  
Risk of all-cause (1-A), cardiovascular (1-B) and non-cardiovascular (1-C) mortality in thirds of composite executive score. Risk of all-cause (1-D), 
cardiovascular (1-E) and non-cardiovascular (1-F) mortality in thirds of composite memory score. 
3 
 
Figure 2. Risk of mortality in thirds of structural brain abnormalities in relation to cognitive assessments 
 
 
Abbreviations: CV: cardiovascular; HR: Hazard Ratio; CI: Confidence Interval.  
Risk of 10-year all-cause mortality in thirds of total brain volume (2-A), white matter hyperintensities (2-B) and cerebral blood flow (2-C) in relation to performance in 
executive function and memory. All results were adjusted for socioeconomic and cardiovascular risk factors. 
 
 
 
 
 
4 
 
Figure 3. Risk of mortality in presence or absence of microbleeds and infarcts in relation to cognitive assessments 
 
Abbreviations: CV: cardiovascular; HR: Hazard Ratio; CI: Confidence Interval. 
Risk of 10-year mortality in presence or absence of microbleeds (3-A) and infarcts (3-B). All results were adjusted for socioeconomic and cardiovascular risk factors.  
 
5 
 
Figure 4. Subgroup analyses on the association of cognitive scores with all-
cause mortality 
 
Abbreviation: CI: Confidence Interval.  
Subgroup analyses on the association between composite executive score (4-A) and composite 
memory score (4-B) with all-cause mortality. 
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Table S-1. Domain-specific cognitive function and risk of 10-years mortality in 
adjusted model containing structural brain abnormalities (n=547) 
  
All-cause Mortality 
 
 
CV Mortality 
 
Non-CV Mortality 
 
Cognitive Domain 
 
 
HR (95%CI) 
 
p-value 
 
HR (95%CI) 
 
 
p-value 
 
HR (95%CI) 
 
p-value 
 
Executive Function  
 
 
1.70 (1.40-2.07) 
 
<0.001 
 
1.86 (1.32-2.61) 
 
<0.001 
 
1.61 (1.26-2.07) 
 
<0.001 
 
Memory  
 
 
1.50 (1.22-1.81) 
 
<0.001 
 
1.47 (1.05-2.04) 
 
0.023 
 
1.53 (1.22-1.92) 
 
<0.001 
 
Abbreviations: CV: Cardiovascular; HR: Hazard Ratio; CI: Confidence Interval. 
Model is adjusted for age, sex, education, body mass index, history of smoking habit, systolic blood pressure, diastolic blood pressure, 
total cholesterol, creatinine, presence of apolipoprotein 4, antihypertensive treatment, statin treatment, history of diabetes, history of 
vascular diseases, total brain parenchymal volume, cerebral blood flow, white matter hyperintensity and the presence of microbleeds and 
infarcts. 
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Table S-2. Domain-specific cognitive function and risk of 10-years mortality (n=547) 
 
  
All-cause Mortality 
 
 
CV Mortality 
 
Non- CV Mortality 
 
Cognitive Domain 
 
 
HR (95%CI) 
 
p-value 
 
HR (95%CI) 
 
 
p-value 
 
HR (95%CI) 
 
p-value 
 
Stroop Colour-Word Test 
 
      
Crude, HR (95%CI) 
 
1.29 (1.20-1.42) <0.001 1.41 (1.24-1.61) <0.001 1.24 (1.10-1.39) <0.001 
Adjusted model 1, HR (95%CI) 
 
1.23 (1.21-1.35) <0.001 1.32 (1.14-1.53) <0.001 1.17 (1.04-1.32) 0.010 
Adjusted model 2, HR (95%CI) 
 
1.22 (1.10-1.36) <0.001 1.29 (1.09-1.53) 0.002 1.19 (1.05-1.35) 0.011 
 
Letter Digit Substitution Test 
 
      
Crude, HR (95%CI) 
 
1.56 (1.37-1.75) <0.001 1.96 (1.56-2.56) <0.001 1.37 (1.16-1.59) <0.001 
Adjusted model 1, HR (95%CI) 
 
1.56 (1.37-1.82) <0.001 2.00 (1.59-2.56) <0.001 1.37 (1.16-1.61) <0.001 
Adjusted model 2, HR (95%CI) 
 
1.56 (1.36-1.81) <0.001 2.01 (1.55-2.58) <0.001 1.40 (1.15-1.65) <0.001 
 
Immediate Picture Learning Test  
 
      
Crude, HR (95%CI) 
 
1.49 (1.33-1.69) <0.001 1.59 (1.28-1.92) <0.001 1.47 (1.27-1.69) <0.001 
Adjusted model 1, HR (95%CI) 
 
1.43 (1.27-1.61) <0.001 1.47 (1.20-1.82) <0.001 1.41 (1.20-1.64) <0.001 
Adjusted model 2, HR (95%CI) 
 
1.49 (1.32-1.70) <0.001 1.45 (1.17-1.83) <0.001 1.43 (1.20-1.69) <0.001 
 
Delayed Picture Learning Test  
 
      
Crude, HR (95%CI) 
 
1.47 (1.32-1.64) <0.001 1.45 (1.19-1.75) <0.001 1.49 (1.30-1.69) <0.001 
Adjusted model 1, HR (95%CI) 
 
1.39 (1.23-1.61) <0.001 1.35 (1.10-1.64) 0.003 1.43 (1.23-1.64) <0.001 
Adjusted model 2, HR (95%CI) 
 
1.48 (1.31-1.69) <0.001 1.36 (1.10-1.63) 0.004 1.46 (1.24-1.69) <0.001 
 
Abbreviations: CV: Cardiovascular; HR: Hazard Ratio; CI: Confidence Interval. 
Model 1: Adjusted for age, sex and education. Model 2: Model 1 adjusted further for body mass index, history of smoking 
habit, systolic blood pressure, diastolic blood pressure, total cholesterol, creatinine, presence of apolipoprotein 4, 
antihypertensive treatment, statin treatment, history of diabetes and history of vascular diseases.  
We used Z-score of each tests to increase the comparability of domain-specific cognitive function. In Stroop Colour-Word Test higher scores 
indicate worse cognitive performance, however, in other tests higher scores indicate better cognitive performance. In all tests best 
performance categorized as the highest third and worst performance as the lowest third. 
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Table S-3. Domain-specific cognitive function and risk of 10-years all-cause 
mortality dependent on the level of brain MRI findings 
 
 
Thirds of Brain Abnormalities 
 
 
 
 
Highest Third 
 
Middle Third 
 
Lowest Third 
 
P for Interaction 
 
Total Brain Volume   
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
1.65 (1.14-2.37) 1.00 (0.82-1.23) 1.53 (1.26-1.86) 0.395 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.53 (1.09-2.15) 1.50 (1.09-2.10) 1.90 (1.53-2.38) 0.160 
Immediate: Fully adjusted, HR (95%CI) 
 
1.11 (0.79-1.54) 1.42 (1.05-1.90) 1.61 (1.32-2.01) 0.065 
Delayed: Fully adjusted, HR (95%CI) 
 
1.21 (0.85-1.64) 1.59 (1.21-2.09) 1.45 (1.17-1.77) 0.405 
 
White Matter Hyperintensity 
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
1.24 (1.00-1.51) 1.31 (1.10-1.55) 1.05 (0.82-1.33) 0.359 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.44 (1.10-1.82) 1.69 (1.32-2.17) 1.37 (1.00-1.92) 0.487 
Immediate: Fully adjusted, HR (95%CI) 
 
1.27 (1.00-1.59) 1.46 (1.19-1.82) 1.45 (1.11-1.92) 0.493 
Delayed: Fully adjusted, HR (95%CI) 
 
1.55 (1.21-1.96) 1.33 (1.06-1.66) 1.55 (1.24-1.96) 0.926 
 
Cerebral Blood Flow 
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
1.37 (0.95-1.95) 1.66 (1.19-2.33) 1.35 (1.12-1.62) 0.293 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.28 (0.90-1.80) 1.92 (1.30-2.86) 1.82 (1.41-2.33) 0.245 
Immediate: Fully adjusted, HR (95%CI) 
 
1.08 (0.80-1.47) 1.39 (1.02-1.92) 1.81 (1.40-2.43) 0.019 
Delayed: Fully adjusted, HR (95%CI) 
 
1.18 (0.88-1.56) 1.61 (1.14-2.27) 1.65 (1.28-2.08) 0.094 
 
Abbreviations: Hazard Ratio; CI: Confidence Interval. 
Model adjusted for age, sex, education, body mass index, history of smoking habit, systolic blood pressure, 
diastolic blood pressure, total cholesterol, creatinine, presence of apolipoprotein 4, antihypertensive treatment, 
statin treatment, history of diabetes and history of vascular diseases.  
We used Z-score of each tests to increase the comparability of domain-specific cognitive function. In Stroop Colour-Word Test 
higher scores indicate worse cognitive performance, however, in other tests higher scores indicate better cognitive 
performance. In all tests best performance categorized as the highest third and worst performance as the lowest third. 
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Table S-4. Domain-specific cognitive function and risk of 10-years all-cause 
mortality dependent on microbleeds and infarcts 
 
 
 
Brain Abnormalities 
 
 
 
 
YES 
 
NO 
 
P for Interaction 
 
Microbleeds 
 
   
Stroop: Fully adjusted, HR (95%CI) 
 
1.89 (1.31-2.74) 1.34 (1.16-1.56) 0.288 
Letter digit: Fully adjusted, HR (95%CI) 
 
2.18 (1.45-3.23) 1.60 (1.32-1.93) 0.450 
Immediate: Fully adjusted, HR (95%CI) 
 
1.29 (0.90-1.88) 1.52 (1.28-1.83) 0.335 
Delayed: Fully adjusted, HR (95%CI) 
 
1.47 (1.06-2.04) 1.45 (1.24-1.70) 0.880 
 
Infarcts 
 
   
Stroop: Fully adjusted, HR (95%CI) 
 
1.27 (1.08-1.50) 1.27 (1.09-1.48) 0.558 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.54 (1.23-1.96) 1.58 (1.28-1.91) 0.889 
Immediate: Fully adjusted, HR (95%CI) 
 
1.32 (1.08-1.62) 1.41 (1.18-1.69) 0.742 
Delayed: Fully adjusted, HR (95%CI) 
 
1.29 (1.06-1.60) 1.38 (1.15-1.65) 0.889 
 
Abbreviations: Hazard Ratio; CI: Confidence Interval. 
Model adjusted for age, sex, education, body mass index, history of smoking habit, systolic blood pressure, 
diastolic blood pressure, total cholesterol, creatinine, presence of apolipoprotein 4, antihypertensive 
treatment, statin treatment, history of diabetes and history of vascular diseases.  
We used Z-score of each tests to increase the comparability of domain-specific cognitive function. In Stroop Colour-Word 
Test higher scores indicate worse cognitive performance, however, in other tests higher scores indicate better cognitive 
performance. In all tests best performance categorized as the highest third and worst performance as the lowest third. 
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Table S-5. Domain-specific cognitive function and risk of 10-years cardiovascular 
mortality dependent on brain MRI findings 
 
 
Thirds of Brain Abnormalities 
 
 
 
 
Highest Third 
 
Middle Third 
 
Lowest Third 
 
P for Interaction 
 
Total Brain Volume   
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
2.43 (1.06-5.46) 1.48 (0.98-2.23) 1.38 (1.01-1.88) 0.423 
Letter digit: Fully adjusted, HR (95%CI) 
 
2.64 (1.25-5.57) 2.35 (1.09-5.01) 2.35 (1.56-2.49) 0.668 
Immediate: Fully adjusted, HR (95%CI) 
 
1.48 (0.74-2.95) 1.31 (0.65-2.69) 1.65 (1.12-2.39) 0.964 
Delayed: Fully adjusted, HR (95%CI) 
 
1.63 (0.83-3.16) 1.36 (0.71-2.58) 1.45 (1.03-2.09) 0.697 
 
White Matter Hyperintensity 
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
1.33 (0.94-1.87) 1.29 (0.98-1.68) 1.27 (0.86-1.86) 0.721 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.68 (1.12-2.58) 2.06 (1.33-3.15) 3.70 (1.67-8.33) 0.248 
Immediate: Fully adjusted, HR (95%CI) 
 
1.44 (0.94-2.19) 1.47 (1.02-2.13) 1.61 (0.91-2.86) 0.892 
Delayed: Fully adjusted, HR (95%CI) 
 
1.86 (1.22-2.87) 1.24 (0.87-1.58) 1.43 (0.87-2.33) 0.308 
 
Cerebral Blood Flow 
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
1.36 (0.74-2.52) 2.33 (1.17-4.64) 1.21 (0.86-1.69) 0.170 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.55 (0.87-2.80) 3.33 (2.00-5.00) 2.44 (1.47-4.17) 0.291 
Immediate: Fully adjusted, HR (95%CI) 
 
1.14 (0.62-2.00) 1.53 (0.81-2.95) 2.01 (1.21-3.25) 0.047 
Delayed: Fully adjusted, HR (95%CI) 
 
1.29 (0.78-2.13) 1.45 (0.71-2.87) 1.61 (1.05-2.44) 0.236 
 
Abbreviations: Hazard Ratio; CI: Confidence Interval. 
Model adjusted for age, sex, education, body mass index, history of smoking habit, systolic blood pressure, 
diastolic blood pressure, total cholesterol, creatinine, presence of apolipoprotein 4, antihypertensive treatment, 
statin treatment, history of diabetes and history of vascular diseases.  
We used Z-score of each tests to increase the comparability of domain-specific cognitive function. In Stroop Colour-Word Test 
higher scores indicate worse cognitive performance, however, in other tests higher scores indicate better cognitive 
performance. In all tests best performance categorized as the highest third and worst performance as the lowest third. 
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Table S-6. Domain-specific cognitive function and risk of 10-years cardiovascular 
mortality dependent on microbleeds and infarcts 
 
 
 
Brain Abnormalities 
 
 
 
 
YES 
 
NO 
 
P for Interaction 
 
Microbleeds 
 
   
Stroop: Fully adjusted, HR (95%CI) 
 
2.37 (1.23-4.55) 1.35 (1.03.75) 0.569 
Letter digit: Fully adjusted, HR (95%CI) 
 
3.43 (1.57-7.12) 2.02 (1.46-2.89) 0.631 
Immediate: Fully adjusted, HR (95%CI) 
 
1.19 (0.64-2.18) 1.63 (1.16-2.29) 0.092 
Delayed: Fully adjusted, HR (95%CI) 
 
1.40 (0.82-2.40) 1.45 (1.07-1.93) 0.549 
 
Infarcts 
 
   
Stroop: Fully adjusted, HR (95%CI) 
 
1.24 (0.95-1.60) 1.49 (1.15-1.93) 0.155 
Letter digit: Fully adjusted, HR (95%CI) 
 
2.09 (1.43-3.05) 1.83 (1.28-2.65) 0.859 
Immediate: Fully adjusted, HR (95%CI) 
 
1.19 (0.85-1.63) 1.80 (1.26-2.57) 0.111 
Delayed: Fully adjusted, HR (95%CI) 
 
1.30 (0.95-1.75) 1.31 (0.95-1.83) 0.849 
 
Abbreviations: Hazard Ratio; CI: Confidence Interval. 
Model adjusted for age, sex, education, body mass index, history of smoking habit, systolic blood pressure, 
diastolic blood pressure, total cholesterol, creatinine, presence of apolipoprotein 4, antihypertensive 
treatment, statin treatment, history of diabetes and history of vascular diseases.  
We used Z-score of each tests to increase the comparability of domain-specific cognitive function. In Stroop Colour-Word 
Test higher scores indicate worse cognitive performance, however, in other tests higher scores indicate better cognitive 
performance. In all tests best performance categorized as the highest third and worst performance as the lowest third. 
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Table S-7. Domain-specific cognitive function and risk of 10-years non-
cardiovascular mortality dependent on brain MRI findings 
 
 
Thirds of Brain Abnormalities 
 
 
 
 
Highest Third 
 
Middle Third 
 
Lowest Third 
 
P for Interaction 
 
Total Brain Volume   
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
1.50 (0.98-2.30) 0.94 (0.72-1.20) 1.64 (1.27-2.11) 0.167 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.33 (0.90-1.96) 1.33 (0.90-1.94) 1.65 (1.22-2.25) 0.116 
Immediate: Fully adjusted, HR (95%CI) 
 
0.95 (0.64-1.42) 1.50 (1.10-2.10) 1.70 (1.25-2.21) 0.048 
Delayed: Fully adjusted, HR (95%CI) 
 
1.06 (0.75-1.57) 1.70 (1.25-2.35) 1.43 (1.11-1.85) 0.244 
 
White Matter Hyperintensity 
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
1.20 (0.92-1.54) 1.32 (1.06-1.62) 0.92 (0.65-1.29) 0.254 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.28 (0.93-1.70) 1.55 (1.14-2.08) 1.01 (0.68-1.46) 0.699 
Immediate: Fully adjusted, HR (95%CI) 
 
1.20 (0.90-1.61) 1.47 (1.13-1.97) 1.39 (0.99-1.92) 0.466 
Delayed: Fully adjusted, HR (95%CI) 
 
1.42 (1.04-1.93) 1.40 (1.07-1.87) 1.56 (1.19-2.08) 0.582 
 
Cerebral Blood Flow 
 
    
Stroop: Fully adjusted, HR (95%CI) 
 
1.45 (0.91-2.28) 1.43 (0.95-2.18) 1.41 (1.12-1.78) 0.821 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.23 (0.82-1.86) 1.40 (0.92-2.15) 1.67 (1.22-2.27) 0.399 
Immediate: Fully adjusted, HR (95%CI) 
 
1.09 (0.76-1.56) 1.29 (0.88-1.85) 1.76 (1.27-2.45) 0.116 
Delayed: Fully adjusted, HR (95%CI) 
 
1.19 (0.83-1.68) 1.62 (1.08-2.39) 1.69 (1.22-2.23) 0.216 
 
Abbreviations: Hazard Ratio; CI: Confidence Interval. 
Model adjusted for age, sex, education, body mass index, history of smoking habit, systolic blood pressure, 
diastolic blood pressure, total cholesterol, creatinine, presence of apolipoprotein 4, antihypertensive treatment, 
statin treatment, history of diabetes and history of vascular diseases.  
We used Z-score of each tests to increase the comparability of domain-specific cognitive function. In Stroop Colour-Word Test 
higher scores indicate worse cognitive performance, however, in other tests higher scores indicate better cognitive 
performance. In all tests best performance categorized as the highest third and worst performance as the lowest third. 
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Table S-8. Domain-specific cognitive function and risk of 10-years non-
cardiovascular mortality dependent on the microbleeds and infarcts 
 
 
 
Brain Abnormalities 
 
 
 
 
YES 
 
NO 
 
P for Interaction 
 
Microbleeds 
 
   
Stroop: Fully adjusted, HR (95%CI) 
 
1.64 (1.05-2.58) 1.32 (1.10-1.61) 0.371 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.70 (1.03-2.79) 1.40 (1.11-1.74) 0.559 
Immediate: Fully adjusted, HR (95%CI) 
 
1.40 (0.88-2.25) 1.53 (1.23-1.85) 0.995 
Delayed: Fully adjusted, HR (95%CI) 
 
1.54 (1.01-2.39) 1.53 (1.23-1.84) 0.813 
 
Infarcts 
 
   
Stroop: Fully adjusted, HR (95%CI) 
 
1.28 (1.02-1.60) 1.19 (0.97-1.43) 0.981 
Letter digit: Fully adjusted, HR (95%CI) 
 
1.23 (0.92-1.67) 1.46 (1.17-1.84) 0.347 
Immediate: Fully adjusted, HR (95%CI) 
 
1.47 (1.09-1.95) 1.32 (1.06-1.61) 0.497 
Delayed: Fully adjusted, HR (95%CI) 
 
1.34 (1.02-1.58) 1.41 (1.15-1.72) 0.805 
 
Abbreviations: Hazard Ratio; CI: Confidence Interval. 
Model adjusted for age, sex, education, body mass index, history of smoking habit, systolic blood pressure, 
diastolic blood pressure, total cholesterol, creatinine, presence of apolipoprotein 4, antihypertensive 
treatment, statin treatment, history of diabetes and history of vascular diseases.  
We used Z-score of each tests to increase the comparability of domain-specific cognitive function. In Stroop Colour-Word 
Test higher scores indicate worse cognitive performance, however, in other tests higher scores indicate better cognitive 
performance. In all tests best performance categorized as the highest third and worst performance as the lowest third. 
 
 
 
 
 
 
 
 
